SCHEMBL2858950

SCHEMBL2858950

CC(=O)Nc1nc2ccc(Oc3ccc(F)c(NC(=O)c4cccc(OC(C)(C)C#N)c4Cl)c3)nc2s1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 16/20 0.74
KDR P35968 11/20 0.74
PDGFRB P09619 3/20 0.63
KIT P10721 2/20 0.63
IKBKB O14920 2/20 0.63
RAF1 P04049 2/20 0.63
CDK1 P06493 2/20 0.63
FGFR3 P22607 2/20 0.63
MAP2K1 Q02750 2/20 0.63
TEK Q02763 2/20 0.63
MAPK14 Q16539 2/20 0.63
AURKB Q96GD4 2/20 0.63
ERBB2 P04626 1/20 0.63
SRC P12931 1/20 0.63
PDGFRA P16234 1/20 0.63
FLT1 P17948 1/20 0.38
RIPK3 Q9Y572 3/20 0.36
RIPK1 Q13546 2/20 0.36
CHEK1 O14757 1/20 0.36
PDGFA P04085 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13185065 0.91 KDR (0.62) BRAFKDRPDGFRBKITIKBKB
SCHEMBL2853206 0.88 BRAF (0.62) BRAFKDRPDGFRBKITIKBKB
SCHEMBL2855668 0.87 KDR (0.73) BRAFKDRPDGFRBKITIKBKB
SCHEMBL2864298 0.84 KDR (0.69) BRAFKDRPDGFRBKITIKBKB
SCHEMBL2853195 0.83 BRAF (0.84) BRAFKDRPDGFRBKITIKBKB
SCHEMBL2853208 0.82 BRAF (0.81) BRAFKDRPDGFRBKITIKBKB
SCHEMBL2857387 0.81 KDR (0.52) BRAFKDRPDGFRBKITIKBKB
SCHEMBL2860510 0.81 KDR (0.56) BRAFKDRPDGFRBKITIKBKB
SCHEMBL2856506 0.80 KDR (0.74) BRAFKDRPDGFRBKITIKBKB
SCHEMBL2851221 0.80 BRAF (1.00) BRAFKDRPDGFRBKITIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 BRAF 1/4885KDR 983/4885PDGFRB 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.